Skip to main content
Skip to footer

Hilde Vanaken

Head Industry Leader, TCS Life Sciences and Healthcare, EFGCP

Many have overlooked the key essence of eConsent because of various interpretations and misconceptions.

This article aims to bring some of the fundamental aspects of eConsent back on track through harmonization while also touching upon its flexibility and value drivers.

Choosing the Consent digital feature(s) for a specific study should be based on a careful assessment of the type of disease, the kind of study, the site(s), and the number of participants. Incorporating more eConsent digital features does not necessarily result in more benefits. It all depends on the value drivers for the participant and investigator.

There is no one size that fits all eConsent models - each disease, each study, each site, and each participant might have different needs. Ultimately, eConsent tools should be flexible, easy to use, and created as paper consent.

Read up on this here to brush up on the eConsent basics and give it the place it deserves!

About the author

Hilde Vanaken
Dr Hilde is a passionate industry leader with +30 years expertise in various drug development domains. She has a track record of turning large and complex programs into realization through collaboration with players among top 10 pharma companies. Partnership is part of Hilde’s DNA. From background, Hilde is a PhD in Medical Sciences, Engineer in Microbiology, and Master in Environmental Sciences, all obtained from the University of Leuven in Belgium.
Read more about authorRead more about author Read more about author

Transformation starts here

Integrated ecosystems are key to better patient outcomes.

Talk to our experts